IN8bio (NASDAQ:INAB) Receives Buy Rating from HC Wainwright

IN8bio (NASDAQ:INAB)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 211.04% from the stock’s current price.

A number of other analysts have also commented on the company. Zacks Research raised IN8bio to a “hold” rating in a research note on Thursday, January 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, IN8bio currently has a consensus rating of “Hold” and an average price target of $5.00.

IN8bio Price Performance

NASDAQ:INAB traded up $0.02 during trading hours on Friday, reaching $1.93. 9,295 shares of the company traded hands, compared to its average volume of 68,648. The firm’s 50-day moving average is $2.01 and its 200-day moving average is $1.99. The stock has a market cap of $18.85 million and a P/E ratio of -0.36. IN8bio has a 1-year low of $1.17 and a 1-year high of $7.50.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Stonepine Capital Management LLC acquired a new stake in shares of IN8bio during the second quarter worth $172,000. Two Sigma Investments LP acquired a new position in IN8bio in the third quarter valued at $107,000. Citadel Advisors LLC acquired a new position in IN8bio in the third quarter valued at $54,000. Texas Capital Bank Wealth Management Services Inc purchased a new position in IN8bio during the fourth quarter worth about $56,000. Finally, Franklin Resources Inc. lifted its position in IN8bio by 381.6% during the fourth quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after buying an additional 724,637 shares during the period. Hedge funds and other institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.